John Batchelor Hotel Mars features Ben Roberts on microgravity medical research, medical products, private sector investment and the ISS National Lab

Hotel Mars with Ben Roberts for Sept. 24, 2025

Summary by Zoom. Edited.

This Hotel Mars program featured a discussion microgravity investor Ben Roberts about the applications and investments in microgravity technology, including its impact on medical treatments, drug formulations, and material sciences. We explored the progress and challenges of commercial space companies in microgravity research and production, with NASA’s support programs playing a crucial role in their development. The conversation covered various applications of low microgravity, the competitive landscape of the industry, and the timeline for product development and market entry.

John Batchelor welcomed Ben Roberts, an investor in microgravity, to discuss the applications and investments in microgravity technology. Ben explained that microgravity refers to the limited effect of gravity in orbit, which enables innovative applications in medical treatments, drug formulations, and material sciences. He highlighted examples such as creating artificial limbs, developing new drugs, and producing high-quality materials that are not possible on Earth due to gravity’s interference. Ben clarified that microgravity applies to any orbit with low enough gravity to affect living systems and material defects, but not enough to eliminate sedimentation or convection.

Ben discussed the progress and challenges of commercial space companies, particularly those involved in microgravity research and production. While basic research on space shuttles and the ISS has been ongoing for decades, commercial companies like Varda and Redwire are just beginning to reach commercialization, producing medical seed crystals and elements. He noted that NASA’s support through programs like SBIR has been crucial in helping these companies transition from pre-commercial to operational phases. The discussion also touched on the financial challenges these companies face, suggesting that private sector or government investment might be needed to bridge the gap until traditional VCs become involved once commercial viability is proven.

Ben continued to discuss various applications of low microgravity, including advanced nanoparticles for drug delivery, accelerated aging studies, and 3D printed cardiac tissue. He explained how these technologies could be more effective when produced in space, despite higher costs. The panelists agreed that while some products could reach the market in 2-5 years, those requiring FDA approval might take longer, with significant progress expected by the 2030s.

Special thanks to our sponsors:Northrup Grumman, American Institute of Aeronautics and Astronautics, Helix Space in Luxembourg, Celestis Memorial Spaceflights, Astrox Corporation, Dr. Haym Benaroya of Rutgers University, The Space Settlement Progress Blog by John Jossy, The Atlantis Project, and Artless Entertainment

Our Toll Free Line for Live Broadcasts: 1-866-687-7223

For real time program participation, email Dr. Space at: drspace@thespaceshow.com

The Space Show is a non-profit 501C3 through its parent, One Giant Leap Foundation, Inc. To donate via Pay Pal, use:

To donate with Zelle, use the email address: david@onegiantleapfoundation.org.

If you prefer donating with a check, please make the check payable to One Giant Leap Foundation and mail to:

One Giant Leap Foundation, 11035 Lavender Hill Drive Ste. 160-306 Las Vegas, NV 89135

Upcoming Programs:

Get full access to The Space Show-One Giant Leap Foundation at doctorspace.substack.com/subscribe